Follow the research questions
Select a topic, then explore the publications connected to this work.
Background
KRAS G12D is the most common KRAS variant in pancreatic cancer but has historically been undruggable. Setidegrasib (ASP3082) is a first-in-class targeted protein degrader designed to eliminate KRAS G12D protein rather than merely inhibit it.
Explore the published evidence
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
First-in-human phase 1 study of setidegrasib (ASP3082), a first-in-class KRAS G12D targeted protein degrader. Among 21 patients with previously treated metastatic PDAC receiving the 600 mg dose, 24% achieved objective response; median PFS and OS were 3.0 and 10.3 months. In NSCLC (n=45), ORR was 36% with median PFS of 8.3 months.
- ORR 24% (PDAC)
- mPFS 3.0 mo (PDAC)
- Phase 1
Background
KRAS G12D is the most common KRAS variant in pancreatic cancer but has historically been undruggable. Setidegrasib (ASP3082) is a first-in-class targeted protein degrader designed to eliminate KRAS G12D protein rather than merely inhibit it.
Results
In this first-in-human phase 1 study, among 21 patients with previously treated metastatic PDAC receiving the 600 mg dose, 24% achieved an objective response; median PFS was 3.0 months and median OS was 10.3 months. Two-thirds of these patients received treatment in the third-line setting or later.
In NSCLC (n=45), the objective response rate was 36% with a median PFS of 8.3 months.